Funding and Grants Leverage ongoing NIH SBIR Phase II funding and Michael J. Fox Foundation grants to position Vincere as a recipient-ready partner for collaborative milestones, enabling co-developments or sponsored research opportunities with priority access to funding-backed programs.

Mitochondrial Target Focus sales conversations on USP30 inhibitors and mitophagy modulation as a novel mechanism with potential disease-modifying impact in neurodegeneration and AKI, aligning with interest from pharma partners seeking first-in-class approaches.

Strategic Partnerships Explore partnerships with consumer health and tech-enabled CROs, given the Beiersdorf collaboration on coenzyme Q10 and Vincere’s computational biology tools, to co-develop mitochondria-targeted formulations or diagnostics that leverage existing distribution channels.

Product Readiness Highlight IND-enabling work and milestone-driven progress to de-risk collaborations, offering potential licensors or co-development partners clear timelines, regulatory readiness, and reduced upfront risk.

Market Positioning Position Vincere as a specialized, small biotech with a focused line of mitochondrial quality control modulators, appealing to niche biopharma seeking accelerated entry into Parkinson’s and age-related disease pipelines through strategic alliances and grant-backed programs.